War Of The White Papers: Grabowski Returns FOB Fire In Debate On Exclusivity
Executive Summary
Duke University Economics Professor Henry Grabowski has returned fire in the academic debate over the amount of time brand companies need to recoup their investment in new biologic products
You may also be interested in...
Follow-on Biologics Vote Time: Eshoo Plans Challenge Of Waxman At House Mark-up
With so many Democratic sponsors, Eshoo appears to need to pick up only nine of the 11 undeclared Republicans in order to pass her brand-friendly legislation.
Obama Budget Counts On FOB Savings For Health Reform – But How, And How Much, Are Open Questions
FDA would receive funds to create infrastructure for allowing drug reimportation, under sketch of 2010 budget.
BIO Wants 14 Years Of Data Exclusivity For Biosimilars; Will Waxman Buy It?
Biotechnology Industry Organization CEO Jim Greenwood has drawn a line in the sand over follow-on biologics: he will not accept less than 14 years of data exclusivity for innovator products. And he says he has the data to back it up